Home  >  Products  >  KLRK1 (killer cell lectin-like receptor subfamily K, member 1 ) Blocking Peptide (the C terminal of KLRK1)(100ug)
KLRK1 (killer cell lectin-like receptor subfamily K, member 1 ) Blocking Peptide (the C terminal of KLRK1)(100ug)

KLRK1 (killer cell lectin-like receptor subfamily K, member 1 ) Blocking Peptide (the C terminal of KLRK1)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-KLRK1 Antibody (ARP63274_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63274
Size: 100ug
Weight: 24kDa
Gene: 22914
Format: Lyophilized powder
Target: Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. NK cells preferentially express several calcium-dependent (C-type) lectins, which have been implicated in the regulation of NK cell function. The NKG2 gene family is located within the NK complex, a region that contains several C-type lectin genes preferentially expressed in NK cells. This gene encodes a member of the NKG2 family. The encoded transmembrane protein is characterized by a type II membrane orientation (has an extracellular C terminus) and the presence of a C-type lectin domain. It binds to a diverse family of ligands that include MHC class I chain-related A and B proteins and UL-16 binding proteins, where ligand-receptor interactions can result in the activation of NK and T cells. The surface expression of these ligands is important for the recognition of stressed cells by the immune system, and thus this protein and its ligands are therapeutic targets for the treatment of immune diseases and cancers. Read-through transcription exists between this gene and the upstream KLRC4 (killer cell lectin-like receptor subfamily C, member 4) family member in the same cluster.
Alternative names: CD314; D12S2489E; FLJ17759; FLJ75772; KLR; NKG2-D; NKG2D
See Full Product Listings >